The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Joseph Osborne
No Relationships to Disclose
 
Matthew Dallos
No Relationships to Disclose
 
Jones Nauseef
No Relationships to Disclose
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Foundation Medicine; Genzyme; Immunomedics; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
Peter Gregos
No Relationships to Disclose
 
Amie Patel
No Relationships to Disclose
 
Angela Tan
No Relationships to Disclose
 
Sharon Singh
No Relationships to Disclose
 
Mahelia Bissassar
No Relationships to Disclose
 
Ana M. Molina
Consulting or Advisory Role - Eisai; Eisai; Eisai; Exelixis; Janssen
 
Paraskevi Giannakakou
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Patents, Royalties, Other Intellectual Property - International Patent Application DOCKET NO. 1676.083WO1 “Identifying Taxane Sensitivity in Prostate Cancer Patients” (Giannakakou, Plymate, co-inventors)
 
Himisha Beltran
Consulting or Advisory Role - Amgen; AstraZeneca; Blue Earth Diagnostics; Foundation Medicine; Janssen Oncology; Pfizer
Research Funding - Abbvie/Stemcentrx (Inst); Bristol Myers Squibb Foundation (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; Medtronic; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Lilly; Sanofi
 
Neil Harrison Bander
Stock and Other Ownership Interests - BZL Biologics; Convergent Therapeutics; Telix Pharmaceuticals
Consulting or Advisory Role - ADC Therapeutics; BZL Biologics; Tarveda Therapeutics; Telix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Cook Urological; Weill Cornell Medical College